An intravenous recombinant bispecific IgG monoclonal antibody that targets PD-L1 and CD47. It blocks PD-L1 to release the PD-1/PD-L1 immune checkpoint and blocks CD47 to disrupt the “don’t-eat-me” signal, enhancing macrophage-mediated phagocytosis and T-cell activation. Phase 1 dose escalation (0.1–6 mg/kg weekly) in advanced solid tumors.
Bispecific IgG that binds PD-L1 and CD47. Blocks PD-L1 to release the PD-1/PD-L1 immune checkpoint and restore T‑cell activation; blocks CD47 to disrupt CD47–SIRPα “don’t‑eat‑me” signaling, promoting macrophage-mediated phagocytosis. Fc effector function can add ADCP/ADCC, enhancing anti-tumor immunity.
YES
DIRECT
IMM2520 binds CD47 on target cells, blocking CD47–SIRPα “don’t‑eat‑me” signaling and engaging Fcγ receptors to drive macrophage-mediated phagocytosis (ADCP) and NK-cell ADCC, leading to death of CD47+ cells.
Third-generation, irreversible, mutant-selective EGFR tyrosine kinase inhibitor (also referred to as almonertinib in some sources).
Third-generation, irreversible, mutant-selective EGFR tyrosine kinase inhibitor that covalently binds the ATP site (e.g., Cys797) of mutant EGFR (including T790M), inhibits EGFR autophosphorylation and downstream MAPK and PI3K–AKT signaling, leading to growth arrest and apoptosis of EGFR-mutant tumor cells with relative sparing of wild-type EGFR.
YES
DIRECT
Irreversible covalent inhibition of mutant EGFR (including T790M) at the ATP site blocks EGFR autophosphorylation and downstream MAPK/PI3K–AKT signaling, leading to growth arrest and apoptosis of EGFR-mutant tumor cells.
Bispecific monoclonal antibody T-cell engager targeting BCMA on myeloma plasma cells and CD3 on T cells, redirecting T-cell cytotoxicity; administered subcutaneously.
Humanized bispecific monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, crosslinking them to activate T-cell cytotoxicity and induce perforin/granzyme-mediated killing of BCMA-expressing myeloma cells.
YES
DIRECT
Teclistamab bridges CD3 on T cells to BCMA on target cells, activating T cells to kill BCMA-expressing cells via perforin/granzyme-mediated cytotoxicity.
Bispecific monoclonal antibody T-cell engager targeting BCMA on myeloma plasma cells and CD3 on T cells, redirecting T-cell cytotoxicity; administered subcutaneously.
Humanized bispecific monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, crosslinking them to activate T-cell cytotoxicity and induce perforin/granzyme-mediated killing of BCMA-expressing myeloma cells.
NO
INDIRECT
Teclistamab binds CD3 on T cells to activate them and crosslink to BCMA+ myeloma cells; CD3+ T cells are not killed—rather, they kill BCMA-expressing targets via perforin/granzyme release.
Anti-CD38 monoclonal antibody mediating ADCC, CDC, and ADCP and depleting immunosuppressive CD38+ cells; administered subcutaneously.
Anti-CD38 monoclonal antibody that binds CD38 on myeloma and immunosuppressive cells and induces cell killing via Fc-mediated ADCC, CDC, and ADCP, depleting CD38+ cells and enhancing antitumor immunity (administered subcutaneously).
YES
DIRECT
Anti-CD38 antibody binds CD38 on target cells; its Fc recruits immune effectors and complement, causing ADCC, ADCP, and CDC to kill CD38+ cells.